Neurotoxicity in patients treated with intravenous polymyxin B: Two case reports

American Journal of Health-System Pharmacy

Volumn 66, Issue 4, 2009, Pages 345-347

  Weinstein, Lenny ^a   Doan, Thien Ly ^a   Smith, Miriam A ^a  

^a LONG ISLAND JEWISH MEDICAL CENTER   (United States)

Author keywords

Antibiotics; Gram negative bacterial infections; Injections; Neurotoxicity syndromes; Polymyxin b; Toxicity

Indexed keywords

ANTIBIOTIC AGENT; CILASTATIN PLUS IMIPENEM; COTRIMOXAZOLE; GENTAMICIN; POLYMYXIN B; ANTIINFECTIVE AGENT;

ABDOMINAL DRAINAGE; ADD ON THERAPY; ADULT; ARTICLE; BACTERIAL INFECTION; BACTERIUM ISOLATION; BLOOD; CASE REPORT; CHOLANGITIS; CHRONIC KIDNEY FAILURE; COLONY FORMING UNIT; DRUG WITHDRAWAL; DYSURIA; ESCHERICHIA COLI; FEMALE; GRAM NEGATIVE BACTERIUM; HEMATURIA; HISTORY; HOSPITAL ADMISSION; HUMAN; HYPERTENSION; INFUSION; KIDNEY FUNCTION; KLEBSIELLA PNEUMONIAE; LEG PARESTHESIA; MALE; NEPHROLITHIASIS; NEUROTOXICITY; OBESITY; ORAL PARESTHESIA; OUTPATIENT; PANCREAS ABSCESS; PANCREAS CYST; PARESTHESIA; PERCUTANEOUS DRAINAGE; PRIORITY JOURNAL; PYURIA; URINALYSIS; URINARY TRACT INFECTION; URINE CULTURE; GRAM NEGATIVE INFECTION; INTRAVENOUS DRUG ADMINISTRATION; MIDDLE AGED; TOXICITY AND INTOXICATION;

ANTI-BACTERIAL AGENTS; FEMALE; GRAM-NEGATIVE BACTERIAL INFECTIONS; HUMANS; INJECTIONS, INTRAVENOUS; MALE; MIDDLE AGED; NEUROTOXICITY SYNDROMES; POLYMYXIN B;

EID: 59849114936     PISSN: 10792082     EISSN: None     Source Type: Journal    
DOI: 10.2146/ajhp080065     Document Type: Article

References (13)

1. Koch-Weser J, Sidel VW, Federman EB et al. Adverse effects of sodium colistimethate: manifestations and specific reaction rates during 317 courses of therapy. Ann Intern Med. 1970; 72:857-68.
2. Evans ME, Feola DJ, Rapp RP. Polymyxin B sulfate and colistin: old antibiotics for emerging multiresistant gram-negative bacteria. Ann Pharmacother. 1999; 33:960-7.
3. Markou N, Apostolakos H, Koumoudiou C et al. Intravenous colistin in the treatment of sepsis from multiresistant gram- negative bacilli in critically ill patients. Crit Care. 2003; 7:R78-83.
4. Levin AS, Barone AA, Penco J et al. Intravenous colistin as therapy for nosocomial infections caused by multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii. Clin Infect Dis. 1999; 28:1008-11.
5. Falagas ME, Kasiakou SK. Toxicity of polymyxins: a systemic review of the evidence from old and recent studies. Crit Care Med. 2006; 10:R27.
6. Arnold TM, Forrest GN, Messmer KJ. Polymyxin antibiotics for gram-negative infections. Am J Health-Syst Pharm. 2007; 64:819-26.
7. Falagas ME, Kasiakou SK. Colistin: the revival of polymyxins for the management of multidrug-resistant gram-negative bacterial infections. Clin Infect Dis. 2005; 40:1333-41. [Erratum, Clin Infect Dis. 2006; 42:1819.]
8. Martynyuk AE, Ucar DA, Yang DD et al. Epilepsy in phenylketonuria: a complex dependence on serum phenylalanine levels. Epilepsia. 2007; 48:1143-50.
9. Hermsen ED, Sullivan CJ, Rotschafer JC. Polymyxins: pharmacology, pharmacokinetics, pharmacodynamics, and clinical applications. Infect Dis Clin North Am. 2003; 17:545-62.
10. Sobieszczyk ME, Furuya EY, Hay CM et al. Combination therapy with polymyxin B for the treatment of multidrug- resistant gram-negative respiratory tract infections. J Antimicrob Chemother. 2004; 54:566-9.
11. Holloway KP, Rouphael NG, Wells JB et al. Polymyxin B and doxycycline use in patients with multidrug-resistant Acinetobacter baumannii infections in the intensive care unit. Ann Pharmacother. 2006;40:1939-45.
12. Linden PK, Kusne S, Coley K et al. Use of parenteral colistin for the treatment of serious infection due to antimicrobial- resistant Pseudomonas aeruginosa. Clin Infect Dis. 2003; 37:el 54-60.
13. Naranjo CA, Busto U, Sellers EM et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981;30:239-45.